Pharmacokinetics and pharmacodynamics of ponesimod, a selective <scp>S1P₁</scp> receptor modulator, in the first‐in‐human study

Abstract

Single doses of ponesimod up to and including 75 mg were well tolerated. The results of this ascending single-dose study indicate an immunomodulator potential for ponesimod and a pharmacokinetic/pharmacodynamic profile consistent with once-a-day dosing.